Recurrent Respiratory Papillomatosis (RRP) Treatment Enters a New Era, Yet Critical Unmet Needs Remain | Thelansis

Thelansis Releases Its 2026 Recurrent Respiratory Papillomatosis (RRP) Emerging Therapy, Unmet Needs, and TPP Insights Report, Mapping The Competitive Landscape Post-First Approval And What Comes Next For Patients, Physicians, And Pharma

Executive Summary
For most of their lives, people with recurrent respiratory papillomatosis (RRP) have known just one reality: repeat surgery. Every few weeks or months, back to the operating table, to shave tumours from the larynx, preserve the airway, and buy a little more time until the papillomas grow back. No drugs. No lasting fix. Just endurance.

That changed in August 2025, when the FDA granted full approval to Papzimeos (zopapogene imadenovec-drba, Precigen), the first-ever approved therapy for adult RRP. A non-replicating adenoviral vector-based immunotherapy targeting HPV 6 and HPV 11, it delivered a 51% complete response rate in its pivotal trial, with durable responses maintained across two years. For a disease that had no approved pharmacological option, this was a landmark.

But one approval does not solve RRP. Juvenile-onset patients remain without a disease-modifying option. Adults with aggressive, HPV 11-driven disease face a pipeline that is still thin. And physicians are already asking: who is the right patient, which line of therapy, and what does long-term management look like when surgery is no longer the only tool in the room?
To answer these questions with the rigour pharma strategy demands, Thelansis Knowledge Partners has published its Recurrent Respiratory Papillomatosis (RRP) - Emerging Therapy, Unmet Needs, and TPP Insights Report 2026. Built on primary research with physicians and KOLs across G8 markets, it offers a ground-level view of the RRP landscape at its most pivotal inflection point in decades.

Request Free Sample of the Recurrent Respiratory Papillomatosis (RRP) - Emerging Therapy, Unmet Needs, and TPP Insights Report 2026: https://thelansis.com/reports/recurrent-respiratory-papillomatosis-rrp-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rrp_tpp

A Rare Disease With a Disproportionate Burden
RRP is caused by persistent infection with HPV 6 or HPV 11 - the same low-risk subtypes responsible for genital warts, but with consequences that are anything but low-risk when they take hold in the larynx. Papillomas grow relentlessly along the aerodigestive epithelium, threatening voice, breathing, and in severe cases, life.
A few numbers put the burden in context:
• Patients average 4.4 surgical procedures per year, and nearly 20 interventions over the lifetime of their disease
• More than 10,000 surgical procedures for RRP are performed annually in the United States alone
• As per Thelansis estimates, over 26,000 adult RRP patients are currently in the US
• Malignant transformation occurs in 3-5% of cases, with pulmonary spread carrying a near-universally fatal prognosis

HPV 11 drives the most aggressive cases - higher surgical frequency, earlier distal spread, and more limited response to standard adjuvant approaches including cidofovir and interferon-alfa. It is also the subtype where the pipeline urgency is greatest, and where KOL frustration with the status quo is most acute.

The Emerging Landscape: Progress, But Still Incomplete
The approval of Papzimeos has validated immunotherapy as a viable mechanism in RRP and sent a signal to developers and investors that this is a space worth entering. With Priority Review, Breakthrough Therapy, and Orphan Drug designations behind it, the regulatory pathway has also been shown to be navigable for innovative approaches.
Close behind, INOVIO's INO-3107, a DNA medicine targeting HPV 6 and 11, had its BLA accepted by the FDA in December 2025, with a PDUFA action date set for October 30, 2026. Filed under the accelerated approval pathway, INO-3107 represents the next potential entrant and a second data point for the DNA vaccine approach in this indication.

Beyond these near-term entries, the broader pipeline remains weighted toward earlier stages, with four Phase II candidates and several programmes in preclinical development. Bevacizumab, an anti-VEGF antibody used off-label in severe cases, continues to play an important clinical role, with recent systematic data reinforcing its value in reducing surgical frequency for select patients, particularly where lesion extension makes surgical access difficult.

Prophylactic HPV vaccination is also emerging as a meaningful adjunct strategy. Recent data indicate that vaccination can significantly extend the interval between surgeries in existing RRP patients, not just prevent new cases, which is prompting clinicians to reconsider where it fits in the management algorithm.

Access comprehensive market analysis on the commercial potential of emerging RRP pipelines by requesting a sample report: https://thelansis.com/reports/recurrent-respiratory-papillomatosis-rrp-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rrp_tpp

Where the Pipeline Falls Short: Unmet Needs That Will Define the Next Wave
The arrival of a first-in-class approval does not mean the unmet need has been addressed. Thelansis' physician research identifies several areas where significant gaps remain:
• No approved therapy for juvenile-onset RRP: The paediatric population, where disease is most aggressive and quality-of-life impact most severe, has been left out of current approval frameworks
• Long-term durability questions: Clinicians want evidence of sustained disease control over years, not the 24-month windows seen in pivotal trials to date
• Functional real-world endpoints: There is a recognised gap between clinical trial outcome measures and the voice and breathing outcomes patients describe as meaningful in daily life
• HPV 11-specific efficacy data: The subpopulation with the most aggressive disease and greatest surgical burden needs clearer, subtype-specific evidence
• Reimbursement and access clarity: KOLs in EU5 and Japan highlight significant uncertainty around payer coverage and patient access, even as approvals arrive

Explore the primary unmet RRP needs defining the next commercial wave, from real-world endpoints to subtype-specific efficacy-download a sample report here: https://thelansis.com/reports/recurrent-respiratory-papillomatosis-rrp-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rrp_tpp

About the Report
RRP - Emerging Therapy, Unmet Needs, and TPP Insights Report - 2026 is designed specifically for pharma strategists, clinical development teams, and commercial decision-makers navigating this space. It covers:
• Full emerging competitive landscape: pipeline analysis, key companies, mechanism of action breakdown, and launch timing estimates
• Clinical trial landscape: target patient segments, trial design, key endpoints, and recruitment criteria
• Unmet needs and opportunity sizing: performance gaps of current therapies, prioritised unmet needs, and where the next entrant can realistically differentiate
• Target product profiles (TPPs): physician-validated attributes and levels, likelihood-to-prescribe data, and expected patient share modelling
• KOL insights: qualitative perspectives from leading physicians on awareness, line of therapy expectations, and which unmet needs emerging therapies are most likely to address
• Geography: G8 coverage - United States, EU5 (France, Germany, Italy, Spain, UK), Japan, and China

Request a sample or explore the full report on Recurrent Respiratory Papillomatosis (RRP) Emerging Therapies, Unmet Needs, and TPP Insights: https://thelansis.com/reports/recurrent-respiratory-papillomatosis-rrp-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rrp_tpp

CONTACT:
Himanshi Negi
Manager - Global BD, and Partnering
Thelansis Knowledge Partners
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.

In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.

For more information about Thelansis and its disease intelligence solutions, visit our website or contact our team.

This release was published on openPR.